Vaishnavi Kundel has funding from the NIH/NHLBI K23HL161324 and AASM Foundation 274-BS-22
S2CID 230783854
has received research support for the University of Florida as principal investigator from Boehringer Ingelheim, Echosens, Inventiva, LabCorp and Perspectum and has served as a consultant for Aligos Therapeutics, Arrowhead, AstraZeneca, 89bio, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Prosciento, Sagimet Biosciences, Siemens USA and Terns Pharmaceuticals
BPC-157 promotes blood vessel formation (angiogenesis) and cytoprotection, while TB-500 facilitates cell migration and tissue remodeling
Melatonin prevents EAAC1 deletion-induced retinal ganglion cell degeneration by inhibiting apoptosis and senescence